Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
JERSEY CITY, N.J., April 06, 2016 -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the 15th Annual Needham Healthcare Conference at The Westin Grand Central Hotel in New York City on Wednesday, April 13, 2016 at 12:10 p.m. ET.
A live webcast will be available on the investors section of the Company's website: www.scynexis.com. A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.
About SCYNEXIS
SCYNEXIS is a pharmaceutical company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and IV drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. For more information, visit www.scynexis.com.
CONTACT: Media Relations Heather Savelle MacDougall Biomedical Communications Tel: 781.235.3060 [email protected] Investor Relations Susan Kim Argot Partners Tel: 212-203-4433 [email protected]
